An analyst from UBS Group AG (NYSE: UBS) recently set a price target of $74.00 for Pharvaris (NASDAQ: PHVS). At the time, the biopharmaceutical stock was trading at $31.25, which means the new target represents a potential increase of about 63.2%. Pharvaris is a late-stage biopharmaceutical company that develops new medicines.
Pharvaris focuses on creating oral treatments for rare diseases, with a specific emphasis on hereditary angioedema (HAE). This condition causes severe and unpredictable swelling. The company is working on a drug called deucrictibant to help patients manage attacks and prevent them from happening.
The positive analyst outlook is supported by the company's strong financial health. As highlighted by GlobeNewswire, Pharvaris recently closed an underwritten offering that raised approximately $132.3 million. An underwritten offering is when investment banks help a company sell its new shares to investors, providing it with fresh capital.
This new funding strengthens the company's financial position. Pharvaris reported having €247 million in cash as of March 31, 2026. This extends its cash runway, which is the amount of time the company can fund its operations before it needs more money, into 2028.
Key clinical milestones also contribute to this outlook. The company expects to release important data from its CHAPTER-3 study in the third quarter of 2026. Furthermore, Pharvaris remains on track to submit a New Drug Application (NDA) for its on-demand HAE treatment in the first half of 2026.
